Meribank Biotech Co

Meribank Biotech Co Financial Leverage

The Financial Leverage (Equity Multiplier) of Meribank Biotech Co (4724.TWO) as of Oct 18, 2026 is 2.30. In the previous year, Financial Leverage (Equity Multiplier) was 2.22 — a change of 3.52% (higher).

Financial Leverage

2.30

YoY

3.52%

Last updated:

Financial Leverage (Equity Multiplier) of Meribank Biotech Co is 2025 2.30 . Financial Leverage (Equity Multiplier) of Meribank Biotech Co was 2024 2.22 . It decreases by 3.52% higher compared to the previous year.

The Meribank Biotech Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.60 TWD
Jan 1, 2020
1.91 TWD
Jan 1, 2021
1.62 TWD
Jan 1, 2022
1.80 TWD
Jan 1, 2023
1.60 TWD
Jan 1, 2024
2.22 TWD
Jan 1, 2025
2.30 TWD
The Meribank Biotech Co Financial Leverage history
YEARFinancial LeverageYoY
2.30+3.52%
2.22+38.60%
1.60-10.65%
1.80+11.11%
1.62-15.27%
1.91+19.56%
1.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Meribank Biotech Co Stock analysis

What does Meribank Biotech Co do? Meribank Biotech Co Ltd, listed on the Taiwan Stock Exchange with ticker 4724.TWO and ISIN TW0004724000, is headquartered in Taipei City, Taiwan. The company went public on June 16, 2023. Meribank Biotech focuses on the research and development of stem cell technologies, specifically providing cord blood (hematopoietic stem cells) storage and application services. It also offers storage and application services for placenta and umbilical cord (mesenchymal stem cells), as well as peripheral blood stem cell storage and application services. The company is involved in promoting stem cell transplantation applications and developing new stem cell processing technologies. Additionally, Meribank Biotech engages in the development of allogeneic umbilical cord mesenchymal stem cell manufacturing and therapeutic applications. The firm’s website is https://www.meribank.com.tw/. No further details on its sector, industry, or specific financial figures are provided in the available information. The company operates within the biotechnology sector, concentrating on stem cell-related services and technologies. Its IPO date marks its entry into the public market, with operations centered on the storage and application of various stem cell types for medical and therapeutic purposes. Meribank Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meribank Biotech Co stock

Financial Leverage (Equity Multiplier) of Meribank Biotech Co is 2.30 in 2025.

Financial Leverage (Equity Multiplier) of Meribank Biotech Co changed from 2.22 to 2.30, representing a 3.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Meribank Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Meribank Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Meribank Biotech Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Meribank Biotech Co